Pancreatic Cancer Research

ResearcherColumbia UniversityActive in the last 2 years

Bernhard Willibald Renz

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9574-8051; OpenAlex author ID A5050415572. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
66
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 2 papers · 2020: 1 paper · 2021: 3 papers · 2022: none · 2023: 3 papers · 2024: none · 2025: 4 papers · 2026: 2 papers

Papers 18

  1. GATA6-CRT axis promotes stress-associated autophagy, EMT, and stemness-associated traits in pancreatic cancer. Co-author DOI 10.1038/s41419-026-08914-8↗
  2. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Last author DOI 10.1155/mi/2632235↗
  3. Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pan… Co-author DOI 10.1016/j.sipas.2025.100320↗
  4. Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreati… First author DOI 10.1097/sla.0000000000006210↗
  5. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC. Co-author DOI 10.1186/s12893-024-02647-1↗
  6. Smad2 Cooperating with TGIF2 Contributes to EMT and Cancer Stem Cells Properties in Pancreatic Cancer via Co-Targeting SOX2. Co-author DOI 10.7150/ijbs.102381↗
  7. In-vitro model to mimic T cell subset change in human PDAC organoid co-culture. Last author DOI 10.1007/s00432-023-05100-7↗
  8. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  9. WNT enhancing signals in pancreatic cancer are transmitted by LGR6. Co-author DOI 10.18632/aging.205101↗
  10. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression. Co-author DOI 10.1136/gutjnl-2019-319912↗
  11. Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matche… Co-author DOI 10.1186/s12893-021-01083-9↗
  12. Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer. First author DOI 10.3390/cancers13112703↗
  13. [Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer]. First author DOI 10.1007/s00104-020-01190-y↗
  14. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Co-author DOI 10.1016/j.suronc.2019.08.010↗
  15. Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update. Last author DOI 10.1097/ppo.0000000000000372↗
  16. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.11.007↗
  17. Oligometastatic Disease in Pancreatic Cancer - How to Proceed? Co-author DOI 10.1159/000455027↗
  18. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). Co-author DOI 10.3390/medsci5020014↗

Closest collaborators

The 25 strongest of 66 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthias Ilmer · 14 shared papers, 2017–2026 · strength 2.22
  2. Jens Werner · 14 shared papers, 2017–2026 · strength 2.10
  3. Jan Goesta D’Haese · 11 shared papers, 2017–2026 · strength 1.75
  4. Hanno Nieß · 6 shared papers, 2019–2025 · strength 0.86
  5. Alexandr V. Bazhin · 4 shared papers, 2021–2025 · strength 0.66
  6. Rainer Christoph Miksch · 3 shared papers, 2021–2026 · strength 0.64
  7. Christoph Benedikt Westphalen · 6 shared papers, 2017–2023 · strength 0.64
  8. Iris Beirith · 4 shared papers, 2021–2025 · strength 0.63
  9. Maximilian Weniger · 3 shared papers, 2019–2026 · strength 0.61
  10. Steffen Ormanns · 3 shared papers, 2023–2025 · strength 0.56
  11. Fuqiang Zu · 2 shared papers, 2025–2026 · strength 0.47
  12. Weiwei Sheng · 2 shared papers, 2025–2026 · strength 0.47
  13. Tengis Tschaidse · 2 shared papers, 2025 · strength 0.42
  14. Yang Feng Wu · 1 shared paper, 2026 · strength 0.29
  15. Qi Li · 1 shared paper, 2026 · strength 0.29
  16. Kathrin Heinrich · 2 shared papers, 2023 · strength 0.28
  17. Hong-jia Wu · 1 shared paper, 2026 · strength 0.24
  18. Ming-qing Wang · 1 shared paper, 2026 · strength 0.24
  19. Hua‐Qin Wang · 1 shared paper, 2026 · strength 0.24
  20. Tao Zhang · 1 shared paper, 2025 · strength 0.23
  21. Ughur Aghamaliyev · 1 shared paper, 2025 · strength 0.23
  22. Guopei Luo · 1 shared paper, 2025 · strength 0.23
  23. Heinz Johannes Buhr · 1 shared paper, 2025 · strength 0.22
  24. Tobias Keck · 1 shared paper, 2025 · strength 0.22
  25. Michael B. Ghadimi · 1 shared paper, 2025 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.